DeLellisRA, LloydRV, HeitzPU, EngC, eds. Pathology and Genetics: Tumours of Endocrine Organs.Lyon, France: IARC Press; (2004.
2.
SantoroM, CarlomagnoF, HayID. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest.1992; 89: 1517–1522.
3.
KrollTG, SarrafP, PecciariniL. PAX8-PPAR gamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science.2000; 289: 1357–1360.
4.
MarquesAR, EspadinhaC, CatarinoAL. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab.2002; 87: 3947–3952.
5.
CastroP, RoqueL, MagalhãesJ, Sobrinho-SimõesM. A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARgamma translocation. Int J Surg Pathol.2005; 13: 235–238.
6.
EngC. RET proto-oncogene in the development of human cancer. J Clin Oncol.1999; 17: 380–393.
7.
NambaH, RubinSA, FaginJA. Point mutations of ras onco-genes are an early event in thyroid tumorigenesis. Mol Endo-crinol.1990; 4: 1474–1479.
8.
CastroP, RebochoAP, SoaresRJ. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab.2006; 91: 213–220.
9.
SoaresP, TroviscoV, RochaAS. BRAF mutations and RET/PTC rearrangements are alternative events in the etio-pathogenesis of PTC. Oncogene.2003; 22: 4578–4580.
10.
SoaresP, Cameselle-TeijeiroJ, Sobrinho-SimõesM. immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid. Histopathology.1994; 24: 205–210.
11.
PleasanceED, StephensPJ, O'MearaS. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature.2010; 463: 184–190.
12.
PleasanceED, CheethamRK, StephensPJ. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature.2010; 463: 191–196.
HolmR, Sobrinho-SimõesM, NeslandJM, SambadeC, JohannessenJV. Medullary thyroid carcinoma with thyroglob-ulin immunoreactivity. A special entity? Lab Invest.1987; 57: 258–268.
15.
KoperekO, PrinzA, ScheubaC, NiederleB, KasererK. Tenascin C in medullary thyroid microcarcinoma and C-cell hyperplasia. Virchows Arch.2009; 455: 43–48.
16.
LimaJ, Teixeira-GomesJ, SoaresP. Germline succinate dehydrogenase subunit D mutation segregating with familial non-RET C cell hyperplasia. J Clin Endocrinol Metab.2003; 88: 4932–4937.
17.
Sobrinho-SimõesM, MáximoV, RochaAS. Intragenic mutations in thyroid cancer. Endocrinol Metab Clin North Am.2008; 37: 333–362.
18.
Abu-AmeroKK, AlzahraniAS, ZouM, ShiY. Association of mitochondrial DNA transversion mutations with familial medullary thyroid carcinoma/multiple endocrine neoplasia type 2 syndrome. Oncogene.2006; 25: 677–684.
19.
Sobrinho-SimoesM. Mixed medullary and follicular carcinoma of the thyroid. Histopathology.1993; 23: 287–289.
20.
MelilloRM, CiraficiAM, De FalcoV. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Am J Pathol.2004; 165: 511–521.
LloydRV, EricksonLA, CaseyMB. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol.2004; 28: 1336–1340.
23.
CaseyMB, LohseCM, LloydRV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol.2003; 14: 55–60.
24.
de MatosPS, FerreiraAP, de Oliveira FacuriF, AssumpcaoLV, MetzeK, WardLS. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology.2005; 47: 391–401.
25.
TroviscoV, Vieira de CastroI, SoaresP. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol.2004; 202: 247–251.
26.
LiuJ, SinghB, TalliniG. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer.2006; 107: 1255–1264.
27.
WidderS, GuggisbergK, KhalilM, PasiekaJL. A pathologic re-review of follicular thyroid neoplasms: the impact of changing the threshold for the diagnosis of the follicular variant of papillary thyroid carcinoma. Surgery.2008; 144: 80–85.
28.
BalochZW, LiVolsiVA. Encapsulated follicular variant of papillary thyroid carcinoma with bone metastases. Mod Pathol.2000; 13: 861–865.
29.
NikiforovaMN, LynchRA, BiddingerPW. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab.2003; 88: 2318–2326.
30.
CoutoJP, PrazeresH, CastroP. How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer. J Clin Pathol.2009; 62: 414–421.
